Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.
Clinical Trial for Metastatic TNBC Now Recruiting
WC3
Posts: 657
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
Description
This phase I trial tests the safety, side effects, and best dose of CF33-hNIS-antiPDL1 in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). CF33-hNIS-antiPDL1 is an oncolytic virus. This is a virus that is designed to infect tumor cells and break them down.
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.